InformAI wins FDA clearance for AI radiation dose planning software

InformAI received FDA 510(k) clearance to market RadOncAI, an AI-enabled software for radiation therapy dose planning in head and neck cancer. The clearance opens the door to U.S. commercialization of cloud and on-premise versions after testing on more than 900 patients.

Why it matters: - RadOncAI is now cleared for U.S. marketing as a software-as-a-medical-device that can help clinicians plan radiation treatment more efficiently. - The software is designed to optimize dose plans for head and neck cancer while reducing exposure to nearby healthy tissue. - InformAI says the product could improve productivity and lower costs in radiation oncology workflows. - About 1 million cancer patients in the U.S. receive radiation therapy each year, making planning efficiency a meaningful clinical and operational issue.

What happened: - InformAI received FDA 510(k) clearance for RadOncAI on July 16, 2026. - RadOncAI is an AI-enabled radiation therapy dose planning tool for head and neck cancer patients. - The company can now market and distribute both cloud-hosted and on-premise versions in the United States. - CEO and Founder Jim Havelka said the clearance advances InformAI’s mission to deliver clinically impactful healthcare software.

The details: - RadOncAI generates an optimized treatment dose plan intended to target tumors while minimizing dose to adjacent healthy tissues. - The software is intended to assist clinicians as a co-pilot, not replace radiation oncologists. - InformAI says the system can produce clinically achievable plans in a fraction of the time used by existing clinical processes. - The development program included clinical research testing on a cohort of more than 900 cancer patients. - The FDA clearance indicates the product met safety and efficacy standards required for 510(k) review. - InformAI said RadOncAI is part of a broader portfolio of AI healthcare applications. - InformAI acknowledged the Cancer Prevention and Research Initiative of Texas for funding the DP220063 grant supporting product development.

Between the lines: - The clearance suggests InformAI is moving from product development into commercial deployment, which can be a key step for medtech companies seeking adoption by hospitals and cancer centers. - The software’s cloud and on-premise options may make it easier to fit different health system IT and data-security requirements. - The company is positioning RadOncAI as a platform that could expand into additional cancer indications.

What's next: - InformAI is now able to sell RadOncAI in the U.S. market. - The company said the software platform is intended to support additional planned cancer indications. - Adoption will likely depend on how well the tool integrates into radiation oncology workflows and whether providers see time and cost savings in practice.